Bio-Techne Corp at UBS Genomics 2.0 and MedTech Innovations Summit Transcript
Good morning, and welcome. Liza Garcia, the UBS Life Science Tools and Diagnostics analyst. I'm joined today by my co-coverage John Sourbeer as well as Jim Hippel, the CFO of Bio-Techne and David Clair, the IR. Well, thank you guys so much for making the trip out.
Thanks very much.
Questions & Answers
Really appreciate it. Let's just start the discussion. Let's maybe you get high level, Jim and background with the earnings, obviously you just reported the end of your fiscal 2023. Can you just walk through the variables that you're monitoring and thinking about as you're thinking about how fiscal 2024 can maybe shake out and the growth outlook, particularly maybe thinking also about the second half, obviously, interesting time?
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
